Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $17.75.
Separately, Canaccord Genuity Group reaffirmed a "buy" rating and set a $17.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, March 11th.
Read Our Latest Analysis on Atara Biotherapeutics
Institutional Trading of Atara Biotherapeutics
Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics in the fourth quarter worth approximately $48,000. Northern Trust Corp bought a new stake in Atara Biotherapeutics in the fourth quarter worth approximately $149,000. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the fourth quarter worth approximately $169,000. Birchview Capital LP bought a new stake in Atara Biotherapeutics in the fourth quarter worth approximately $293,000. Finally, Marshall Wace LLP acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter worth $332,000. 70.90% of the stock is owned by institutional investors.
Atara Biotherapeutics Price Performance
ATRA traded up $0.81 on Friday, reaching $9.23. 93,242 shares of the company traded hands, compared to its average volume of 126,018. The stock's 50 day moving average price is $6.93 and its 200-day moving average price is $8.81. Atara Biotherapeutics has a 52-week low of $5.01 and a 52-week high of $18.71. The company has a market cap of $55.02 million, a price-to-earnings ratio of -0.36 and a beta of 0.19.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of ($3.07) by $6.57. The company had revenue of $98.10 million for the quarter, compared to analysts' expectations of $4.30 million. As a group, equities research analysts forecast that Atara Biotherapeutics will post -10.39 earnings per share for the current fiscal year.
Atara Biotherapeutics Company Profile
(
Get Free ReportAtara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Further Reading
Before you consider Atara Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atara Biotherapeutics wasn't on the list.
While Atara Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
